



THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/530,262

Filed: April 5, 2002

1st Inventor: M. Koike

For: Solid Preparation

Atty. Dkt. No. 3113 US0P

Art Unit: tba

Examiner: tba

Allowed:

Batch:

Paper No.:

Information Disclosure Statement

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 23313-1450

Sir:

Pursuant to 37 CFR §1.56, 1.97 and 1.98, Applicants' request consideration of the reference listed on the attached form PTO-1449 under §1.97(b).

This statement is being timely filed before the mailing of a first Office Action on the merits. No fee is required for this filing.

Should the Examiner believe that a conference with Applicants' attorney would advance prosecution of this application, the Examiner is respectfully invited to call Applicants' attorney.

Respectfully submitted,

Dated: July 13, 2005

(847) 383-3391

(847) 383-3372

Elaine M. Ramesh
Elaine M. Ramesh, Ph.D., Reg. No. 43,032
Mark Chao, Ph.D., Reg. No. 37,293
Attorney for Applicants
Customer No. 23115

Takeda Pharmaceuticals North America, Inc.
Intellectual Property Department
475 Half Day Road
Lincolnshire, IL 60069 USA

U.S. Patent Application Serial No.: 10/530,262

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.W./

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/530,262
Filing Date	April 5, 2005
First Named Inventor	M. Koike
Art Unit	tba
Examiner Name	tba
Attorney Docket Number	3113 US0P

Sheet

1

of

2

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
/R.W./		US- 6,153,632	11-28-2000	R. Rieveley	
↓		US- 6,291,495	09-18-2001	R. Rieveley	
		US- 2002/0004515	01-10-2002	S. Smith	
		US- 6,524,621	02-25-2003	A. Adjei et al.	
		US- 6,403,121	06-11-2002	A. Adjei et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ *Number ⁴ *Kind Code ⁵ (if known)				
/R.W./		WO 00/28989	05-25-2000	SmithKline Beecham P.L.C.		
↓		WO 99/47128	09-23-1999	Bristol-Myers Squibb Co.		
		WO 01/82875	11-08-2001	Aeropharm Technology		
		WO 98/57634	12-23-1998	SmithKline Beecham P.L.C.		
		EP 0 749 751	12-27-1996	Takeda Chemical Industries		
		WO 2004/006921 (Abstract Only)	01-22-2004	Takeda Chemical Industries		✓

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.W./

10530262 - GAU: 4131



10530262 - GAU: 4131

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number 10/530,262

Filing Date April 5, 2005

First Named Inventor M. Koike

Art Unit tba

Examiner Name tba

Sheet 1 of 1 Attorney Docket Number 3113 USOP

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/R.W./		M. SUZUKI, et al., "Effects of Combined Pioglitazone and Metformin on Diabetes and Obesity in Wistar Fatty Rats", <u>Clinical and Experimental Pharmacology and Physiology</u> , (2002) Vol. 29, No. 4, pages 269-274	
↓		SHIN. YAKUZAIGAKU SORON (Kaitei Dai 3 Han), "Introduction to Modern Pharmaceutics", <u>Nankodo Co., Ltd.</u> , (1987), pages 155-160	✓

Examiner Signature	/Rachael Welter/	Date Considered	04/30/2008
-----------------------	------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.W./